Detailed Program
Monday, October 28, 2024
-
07:00
Registration opens
-
08:00-08:15
Welcome and Introductory CommentsWelcome from: Jon Odorico and James Markmann
-
08:15-09:30
Session 1
Insights from Islet Biology for Making Stem Cell-Derived IsletsModerator: Albert Hwa
-
08:15-08:30
Insights into islet biology from the human pancreas and beyondAlvin Powers, Vanderbilt University, United States -
08:30-08:45
Insights into beta cell development from stem cellsMatthias Hebrok, Technical University of Munich, Germany -
08:45-09:00
Using stem cell islets to gain insights into human pancreas developmentDanwei Huangfu, Memorial Sloan Kettering, United States -
09:00-09:15
Using human pancreas slices to understand islet physiology and functionJoana Collares Pereira Almaca, University of Miami School of Medicine, United States -
09:15-09:30
Panel Discussion
-
09:30-10:00
Coffee Break
-
10:00-11:15
Session 2
Optimizing Differentiation to Stem Cell Beta CellsModerator: Cristina Nostro
-
10:00-10:15
Tuning developmental signaling during stem cell-derived islet differentiationNathaniel Hogrebe, Washington University School of Medicine, United States -
10:15-10:30
Functional maturation of stem cell isletsDiego Balboa, University of Helsinki, Finland -
10:30-10:45
Origin and development of off-target cell populations arising during stem cell to islet differentiationChristian Honoré, Cell Therapy R&D, Novo Nordisk A/S, Denmark -
10:45-11:00
Scalable generation of 3D stem cell islet organoids or Hallmarks and triggers of beta cell maturationJuan Alvarez-Dominguez, University of Pennsylvania, United States -
11:00-11:15
Panel Discussion
-
11:15-11:30
Stretch Break
-
11:30-12:45
Session 3
Immunology of T1DModerator: Lorenzo Piemonti
-
11:30-11:45
Type 1 diabetes as a disease of the beta-cellBart Roep, Leiden University Medical Center, Netherlands -
11:45-12:00
Neoantigens and autoimmunity triggering mechanismsEddie James, Benroya Research Institute, United States -
12:00-12:15
Tracking antigen-specific T cell receptors during T1D progressionMaki Nakayama, University of Colorado, United States -
12:15-12:30
Modeling the immune infiltration of human stem cell-derived islets in vivoRemi Creusot, Columbia University, United States -
12:30-12:45
Panel Discussion
-
12:45-13:45
Lunch Break, Poster Viewing & Group Photo
-
13:45-14:15
Keynote AddressIntroduction: Doug Melton
-
13:45-14:15
Disease Modifying Therapies and rationale for combining with stem cell isletsTom Kay, St Vincent's Hospital, Australia
-
14:15-15:15
Session 4A
Best Abstracts Session IModerator: Antonio Citro
-
Abstract 1
Anja IvisStrategies for preventing the formation of cytotoxic IAPP amyloid in human stem cell-derived islets -
Abstract 2
Hong QianDevelopment of a biovascular pancreas to deliver stem cell-derived islets as a therapy for type 1 diabetes -
Abstract 3
Anup NairModeling the effects of early hyperinsulinemia due to the R1420H SUR1 mutation using isogenic iPSC derived pancreatic Islets -
Abstract 4
Sophia KioulaphidesHuman stem cell-derived beta-cells delivered with vasculogenic hydrogels reverse hyperglycemia in diabetic immunodeficient mice -
Abstract 5
Veronica CochraneSC-beta cell MafA expression: for better or worse -
Abstract 6
Paraish MisraIslet versus enterochromaffin lineage allocation of hPSC-derived pancreatic progenitors can be modulated at both pre-progenitor and post-progenitor stages
-
15:15-15:45
Coffee Break
-
15:45-16:45
Session 4B
Best Abstracts Session IIModerator: Tom Kay
-
Abstract 1
Pere CatalaUltrafast Volumetric Bioprinting of an Endocrine Pancreas Using Functional Human iPSC-Derived Islets -
Abstract 2
Francesco CampoBio-fabrication of a Human iPSC-based vascularized endocrine pancreas for the treatment of Type 1 Diabetes -
Abstract 3
Saleth DharmarajA perfusable encapsulation device housing Stem cell derived pseudo-islets to treat type-1 diabetes -
Abstract 4
Ji LeiIdentifying optimal engraftment sites for human stem cell-derived islets in a non-Human primate model -
Abstract 5
Nicole WojcikOptimization of immunosuppression for beta cell replacement therapy: assessing the tolerability and efficacy of belatacept combined with reduced tacrolimus -
Abstract 6
Daniel TremmelIslet vascularized ECM organoid (IVEO) constructs repair isolated islets native environment for successful engraftment and functionality post-transplantation
-
16:45-18:00
Session 5
Immune Evasive IsletsModerator: Holger Russ
-
16:45-17:00
PIDO induced islet immune protection from allo and xeno immunityJacques Galipeau, University of Wisconsin School of Medicine and Public Health, United States -
17:00-17:15
Hypoimmune Stem Cell IsletsSonja Schrepfer, Sana Biotechnology, United States -
17:15-17:30
Genome editing of stem cell islets for hypoimmunityAudrey Parent, University of California San Francisco Diabetes Center, United States -
17:30-17:45
Combinatorial genome engineering strategy for antigen specific protection of stem cell derived beta cells by CAR TregsJessie Barra, University of Florida College of Medicine, United States -
17:45-18:00
Panel Discussion
-
18:00-18:05
Day One Wrap Up
-
18:05-19:30
Networking Reception
Tuesday, October 29, 2024
-
07:00
Registration opens
-
07:30-08:45
Session 6
Beta Cell Replacement Clinical Trials UpdateModerator: Jon Odorico
-
07:30-07:50
Vertex Trials UpdateMichael Rickels, University of Pennsylvania, United States -
07:50-08:10
CD40L immunosuppression and Sernova Islet transplant trialsPiotr Witkowski, Transplant Institute University of Chicago Medicine, United States -
08:10-08:30
Parathyroid gland supplemented human islet engraftment and function in humansPeter Stock, University of California San Francisco, United States -
08:30-08:45
Panel Discussion
-
08:45-09:00
Stretch Break
-
09:00-10:15
Session 7
Immunomodulation/EncapsulationModerator: James Markmann
-
09:00-09:15
Overview of Immunomodulation StrategiesAlessandro Grattoni, Houston Methodist Hospital, United States -
09:15-09:30
Role of EVs in Immunomodulation of stem cell isletsEdward Phelps, University of Florida, United States -
09:30-09:45
CD40L immunotherapy to protect transplanted isletsNorma Kenyon, University of Miami Miller School of Medicine, United States -
09:45-10:00
The Good and Bad of Humanized Mouse ModelsMichael Brehm, University of Massachusetts Chan Medical School, United States -
10:00-10:15
Panel Discussion
-
10:15-10:45
Coffee Break
-
10:45-12:00
Session 8
Overcoming challenges to broader clinical application of stem cell-derived isletsModerator: Esther Latres
-
10:45-11:00
Successful cryopreservation of intact stem cell isletsJoseph Sushil Rao, University of Minnesota, United States -
11:00-11:15
Delivering insulin-producing cells without immunosuppressionMinglin Ma, Cornell University, United States -
11:15-11:30
Novel scale up technologiesKevin Alessandri, TreeFrog Therapeutics, United States -
11:30-12:00
Panel Discussion
-
12:00-13:00
Lunch Break & Poster Viewing
-
13:00-13:30
Session 9
Best Abstracts Session IIIModerator: Michael Rickels
-
Abstract 1
Sonja SchrepferHypoimmune Islet Cells Mediate Insulin Independence After Allogeneic Transplantation Without Immunosuppression -
Abstract 2
Kfir MolakandovIsletRxPlus, CD26− and CD49A+ enriched hESC-derived Islet cells, improves safety and identity profile in diabetic mice at multiple implantation sites. -
Abstract 3
Caterra LeavensThe beta cell “invisibility cloak” – Developing stem cell-derived pancreatic islets that are protected from the immune system -
Abstract 4
Mina SeedhomStudy of interactions between human immune systems and SC-islets from T1D individuals in a novel NSG MHC-DKO Tg(hIL15) mouse
-
13:30-15:05
Session 10
Future Opportunities And Barriers for Broad Clinical Application
-
13:30-14:15
Panel 1
Manufacturing, Scale Up, Regulatory
Moderator: Jeffrey Millman
Felicia Pagliuca, Vertex Pharmaceuticals, Inc. United States
Heather Lombardi, FDA - CBER, United States
Tom Bollenbach, BiofabUSA, United States -
14:20-15:05
Panel 2
Eligibility Criteria and Future Clinical Trial Design
Moderator: Eelco DeKoning
Lorenzo Piemonti, Universita Vita-Salute San Raffaele, Italy
Trevor Reichman, U Toronto, Canada
Marjana Marinac, Breakthrough T1D, United States
-
15:05-15:10
Closing